[Form 4] Agios Pharmaceuticals, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Rahul Ballal, a director of Agios Pharmaceuticals (AGIO), reported a transaction dated 08/11/2025 involving restricted stock units and common stock. The filing records a grant of 2,302 restricted stock units, each representing a contingent right to receive one share, originally granted on 08/11/2022; the underlying shares vest in three equal annual installments beginning 08/11/2023. The report shows a price of $0 for the restricted units.

Following the reported transaction the filing shows Mr. Ballal beneficially owns 12,414 shares of Agios common stock in a direct capacity.

Positive

• Reported direct beneficial ownership of 12,414 common shares
• Grant of 2,302 restricted stock units documented with explicit vesting schedule

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine director equity grant with modest change to reported ownership; not materially market-moving.

The Form 4 documents a grant-related entry for 2,302 restricted stock units and reports total direct beneficial ownership of 12,414 common shares. The RSUs were granted on 08/11/2022 and vest in three equal annual installments beginning 08/11/2023, and the filing lists a price of $0 for the units. This is a standard equity-compensation disclosure by an insider; it does not indicate sales or acquisitions for cash and thus is unlikely to affect short-term market valuation by itself.

Corporate Governance Expert

TL;DR: Equity grant follows a multi-year vesting schedule consistent with director incentives; disclosure appears complete.

The filing states the restricted stock units were granted on 08/11/2022 with vesting in three equal annual installments beginning 08/11/2023, which is a common structure to align long-term director interests with shareholders. The report indicates direct beneficial ownership of 12,414 shares after the reported transaction. No departures, dispositions for cash, or unusual terms are disclosed in the document provided.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ballal Rahul D.

(Last) (First) (Middle)

C/O AGIOS PHARMACEUTICALS, INC.

88 SIDNEY STREET

(Street)

CAMBRIDGE MA 02139

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AGIOS PHARMACEUTICALS, INC. [ AGIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock	08/11/2025		M		2,302	A	$0	12,414	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted stock units	(1)	08/11/2025		M			2,302	(2)	(2)	Common stock	2,302	$0	0	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

2. The restricted stock units were granted on August 11, 2022. Beginning on August 11, 2023, the shares underlying the restricted stock units will vest in three equal annual installments.

Remarks:

	/s/ William Cook, as attorney-in-fact for Rahul Ballal	08/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Rahul Ballal report on the AGIO Form 4?

The Form 4 reports a transaction dated 08/11/2025 involving 2,302 restricted stock units and shows 12,414 shares of common stock beneficially owned following the reported transaction.

How many restricted stock units were involved and what do they represent?

The filing lists 2,302 restricted stock units, and states each unit represents a contingent right to receive one share of Agios common stock.

When were the restricted stock units granted and how do they vest?

The restricted stock units were granted on 08/11/2022 and the filing states they vest in three equal annual installments beginning 08/11/2023.

What price is shown for the reported units or shares?

The Form 4 shows a price of $0 for the restricted stock units in the reported transaction.

What is Rahul Ballal's relationship to Agios Pharmaceuticals (AGIO)?

The filing identifies Rahul Ballal as a Director of Agios Pharmaceuticals.